MARKET

RLYB

RLYB

Rallybio Corp
NASDAQ
14.40
+0.19
+1.34%
Opening 11:11 05/15 EDT
OPEN
14.16
PREV CLOSE
14.21
HIGH
14.50
LOW
13.91
VOLUME
15.77K
TURNOVER
--
52 WEEK HIGH
15.31
52 WEEK LOW
2.160
MARKET CAP
76.17M
P/E (TTM)
-9.0288
1D
5D
1M
3M
1Y
5Y
1D
ADAR1 Capital reports $711,243 Rallybio common shares purchase
PUBT · 1d ago
Rallybio Q1 FY26 net loss narrows to $8.28 million; revenue flat at $212,000
PUBT · 1d ago
Weekly Report: what happened at RLYB last week (0504-0508)?
Weekly Report · 4d ago
Alibaba, Cisco To Report Earnings; Inflation Numbers In Focus
Seeking Alpha · 6d ago
Catalyst Watch: Cerebras headlines AI-related IPO blitz, CPI print and 13Fs
Seeking Alpha · 6d ago
ADAR1 Capital Management acquires Rallybio common shares worth $2,183,857.51
PUBT · 05/07 01:33
Rallybio initial beneficial ownership filing shows ADAR1 Capital Management stake of 623,879 shares
PUBT · 05/07 01:31
BUZZ-U.S. STOCKS ON THE MOVE-Mirum Pharma
Reuters · 05/04 18:05
More
About RLYB
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.

Webull offers Rallybio Corp stock information, including NASDAQ: RLYB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLYB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLYB stock methods without spending real money on the virtual paper trading platform.